Elvitegravir/cobicistat/emtricitabine/tenofovir
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Elvitegravir | Integrase inhibitor |
| Cobicistat | Cytochrome P450 inhibitor |
| Emtricitabine | Reverse-transcriptase inhibitor |
| Tenofovir disoproxil fumarate | Reverse-transcriptase inhibitor |
| Clinical data | |
| Trade names | Stribild |
| AHFS/Drugs.com | entry |
| Pregnancy cat. | B (US) |
| Legal status | ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| ATC code | J05AR09 |
Elvitegravir/cobicistat/emtricitabine/tenofovir also known as the Quad pill (brand name Stribild) is a fixed dose combination drug for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting liver enzymes that metabolize the other components. Stribild gained approval by U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination.
References [edit]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
